Edition:
United Kingdom

Iovance Biotherapeutics Inc (IOVA.OQ)

IOVA.OQ on NASDAQ Stock Exchange Global Market

9.05USD
15 Dec 2017
Change (% chg)

$0.90 (+11.04%)
Prev Close
$8.15
Open
$8.15
Day's High
$9.50
Day's Low
$8.15
Volume
1,940,063
Avg. Vol
129,916
52-wk High
$9.50
52-wk Low
$4.45

Latest Key Developments (Source: Significant Developments)

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017.IOVANCE BIOTHERAPEUTICS - SELECTED ITS GEN 2 MANUFACTURING PROCESS FOR ALL THREE PHASE 2 TRIALS, ALL FUTURE TIL CLINICAL DEVELOPMENT.IOVANCE - PROTOCOLS FOR 3 EXISTING STUDIES HAVE BEEN AMENDED TO ALLOW ENROLLMENT OF NEW PATIENTS WITH TIL MANUFACTURED WITH GEN 2 PROCESS.IOVANCE - COHORT 1 OF C-144-01 MELANOMA STUDY WILL BE CLOSED AND NEW PATIENTS WILL BE ENROLLED IN COHORT 2.IOVANCE - PHASE 2 STUDY IN PD-1 AND PD-L1 NAÏVE NSCLC PATIENTS WILL INITIATE IN H1 2018.IOVANCE - MD ANDERSON CANCER CENTER TO INITIATE 2 BASKET STUDIES IN SARCOMA & PLATINUM RESISTANT OVARIAN CANCER.IOVANCE - CO RETAINS RIGHTS TO MDA PRECLINICAL RESEARCH IN EXPANDING UNDERSTANDING OF TIL, RELATED INTELLECTUAL PROPERTY.  Full Article

Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Biolife Solutions Inc ::BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS.BIOLIFE SOLUTIONS - EXECUTED AGREEMENT TO SUPPLY CRYOSTOR CELL FREEZE MEDIA AND HYPOTHERMOSOL STORAGE AND SHIPPING MEDIA TO IOVANCE BIOTHERAPEUTICS.  Full Article

Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Iovance Biotherapeutics Inc :Iovance Biotherapeutics Inc reports third quarter 2017 financial results.Q3 non-GAAP loss per share $0.31.Q3 GAAP loss per share $0.35.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Iovance Biotherapeutics Inc - ‍anticipates cash, cash equivalents and short-term investments as of December 31, 2017, to be in excess of $141.0 million​.  Full Article

Lion biotechnologies reports qtrly loss per share of $1.15
Friday, 4 Nov 2016 

Lion Biotechnologies Inc : Lion Biotechnologies reports third quarter 2016 financial results and provides corporate update . Says Q3 adjusted loss per share of $0.17 . Qtrly loss per share $1.15 . Company appoints new CFO, Greg Schiffman .Company plans to initiate Phase 2 trials for LN-145 for potential treatment of head and neck and cervical cancers in 2017.  Full Article

Lion Biotechnologies names Gregory Schiffman as CFO
Monday, 3 Oct 2016 

Lion Biotechnologies Inc : Says appointment of Gregory T. Schiffman, as chief financial officer of company, effective immediately .Lion Biotechnologies appoints Gregory Schiffman as chief financial officer.  Full Article

Lion Biotechnologies announces 5-yr extension of national cancer institute CRADA
Wednesday, 24 Aug 2016 

Lion Biotechnologies Inc : Lion Biotechnologies announces 5-year extension of national cancer institute CRADA for development of novel til immuno-oncology therapies . Financial terms of CRADA were not changed .To extend CRADA for an additional five-year term until 2021.  Full Article

Lion Biotechnologies expects to invest $35-$40 mln in research, development, operations
Monday, 8 Aug 2016 

Lion Biotechnologies Inc :Lion anticipates that it will now invest between $35 million and $40 million in its research, development and operations for 2016.  Full Article

Lion Biotechnologies says CFO Molly Henderson provides employment termination notice
Friday, 8 Jul 2016 

Lion Biotechnologies : Molly henderson, CFO provides board with written notice that she would terminate her employment effective August 16, 2016 .Intends to relocate certain of its executive office operations, including those of CFO, to California, in near future.  Full Article

Lion Biotechnologies files for common stock offering of up to 9.7 mln shares
Friday, 1 Jul 2016 

Lion Biotechnologies Inc :files for common stock offering of up to 9.7 million shares by selling stockholders - Sec filing.  Full Article

Lion Biotechnologies raises about $100 mln in private placement
Friday, 3 Jun 2016 

Lion Biotechnologies Inc : Lion Biotechnologies raises approximately $100 million in private placement . Says purchase price will be $4.75 for each share of common stock and $4.75 for each share of series B preferred stock . Investors agreed to purchase a total of 9.7 million shares, about 11.4 million shares of newly authorized series B preferred stock .Each share of series B preferred stock will become convertible into one share of common stock.  Full Article

BRIEF-Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates

* IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017